[癌症患者的组织因子与静脉血栓栓塞]
[Tissue factors and venous thromboembolism in cancer patients].
作者信息
Zhu Huiqi, Ying Kejing
机构信息
Department of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, National Regional Medical Center for Respiratory Diseases, Hangzhou 310016, China.
出版信息
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 Dec 25;49(6):772-778. doi: 10.3785/j.issn.1008-9292.2020.12.13.
Malignant tumor is one of the important acquired risk factors of venous thromboembolism (VTE). As the transmembrane receptor of coagulation factor Ⅶ and activated coagulation factor Ⅶa , tissue factor is the main initiator of exogenous coagulation. Tissue factor positive particles expressed and released by tumor cells enter the circulation and mediate thrombosis in patients with surgical treatment and distant tumor metastasis; the enhanced procoagulant activity of tissue factor after chemotherapy makes many cancer patients more likely to develop thromboembolic disease. Tissue factors can also be used to predict the risk of VTE in patients with pancreatic cancer, colorectal cancer and ovarian cancer.This article summarizes the role of tissue factor in VTE of cancer patients at different treatment stages, and further clarifies the relationship between tissue factor and the risk of VTE in cancer patients.
恶性肿瘤是静脉血栓栓塞症（VTE）重要的后天危险因素之一。组织因子作为凝血因子Ⅶ及活化凝血因子Ⅶa的跨膜受体，是外源性凝血的主要启动因子。肿瘤细胞表达并释放的组织因子阳性颗粒进入循环，在接受手术治疗及发生远处肿瘤转移的患者中介导血栓形成；化疗后组织因子促凝活性增强，使许多癌症患者更易发生血栓栓塞性疾病。组织因子还可用于预测胰腺癌、结直肠癌和卵巢癌患者发生VTE的风险。本文总结了组织因子在癌症患者不同治疗阶段VTE中的作用，并进一步阐明了组织因子与癌症患者VTE风险之间的关系。
Zotero 插件